These three biotech stocks are worth buying this month.
News & Analysis: Innoviva Common Stock
An activist hedge fund is shaking things up at Innoviva.
Just before Innoviva released its third-quarter results on Wednesday afternoon, the stock fell sharply. What gives?
Innoviva's proxy battle with an activist hedge fund for board seats leaves shareholders disappointed.